Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib

被引：0
|
作者：
Cheung, Justin Matthew
Kang, Jiyoon
Yeap, Beow Y.
Peterson, Jenn
Do, Andrew
Digumarthy, Subba R.
Gainor, Justin F.
Lin, Jessica Jiyeong
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21079
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
    Goto, Yasushi
    Kenmotsu, Hirotsugu
    Tamiya, Motohiro
    Murakami, Shuji
    Kurata, Takayasu
    Yanagitani, Noriko
    Taniguchi, Hirokazu
    Kuyama, Shoichi
    Shimizu, Junichi
    Yokoyama, Toshihide
    Shimada, Naoko
    Maeda, Tadashi
    Tamiya, Akihiro
    Uchiyama, Ayumi
    Imaizumi, Kazuyoshi
    Takahama, Takayuki
    Kato, Terufumi
    Hayashi, Hidetoshi
    Shiraiwa, Naoko
    Toyoizumi, Shigeyuki
    Kikkawa, Hironori
    Thomaidou, Despina
    Nishio, Makoto
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
  • [42] Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
    Verran, Julian
    Mathavan, Vidya
    CASE REPORTS IN HEMATOLOGY, 2022, 2022
  • [43] Analysis of significant weight gain in patients using alectinib for ALK-positive lung cancer
    Sikkema, Barend Joel
    de Leeuw, Simon
    Pruis, Melinda
    Mohseni, Mostafa
    Veerman, Geerten Dieuwert Marijn
    Paats, Marthe
    Dumoulin, Daphne W.
    Smit, Egbert F.
    Schols, Annemie M. W. J.
    Mathijssen, Ron H. J.
    Van Rossum, Elisabeth
    Dingemans, Anne-Marie C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer
    de Leeuw, Simon P.
    Pruis, Melinda A.
    Sikkema, Barend J.
    Mohseni, Mostafa
    Veerman, G. D. Marijn
    Paats, Marthe S.
    Dumoulin, Daphne W.
    Smit, Egbert F.
    Schols, Annemie M. W. J.
    Mathijssen, Ron H. J.
    van Rossum, Elisabeth F. C.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1017 - 1030
  • [45] Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutationEfficacy of alectinib against ALK G1269A mutated cells
    Yasushi Yoshimura
    Mitsue Kurasawa
    Keigo Yorozu
    Oscar Puig
    Walter Bordogna
    Naoki Harada
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 623 - 628
  • [46] PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer
    Liu, X.
    Pan, Y.
    Zhang, W.
    Zhou, C.
    Wu, C.
    Ren, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S675 - S676
  • [47] Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
    Ou, Sai-Hong Ignatius
    Nishio, Makoto
    Ahn, Myung-Ju
    Mok, Tony
    Barlesi, Fabrice
    Zhou, Caicun
    Felip, Enriqueta
    de Marinis, Filippo
    Kim, Sang-We
    Perol, Maurice
    Liu, Geoffrey
    Migliorino, Maria Rita
    Kim, Dong-Wan
    Novello, Silvia
    Bearz, Alessandra
    Garrido, Pilar
    Mazieres, Julien
    Morabito, Alessandro
    Lin, Huamao M.
    Yang, Hui
    Niu, Huifeng
    Zhang, Pingkuan
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1404 - 1414
  • [48] Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
    Uemura, Takehiro
    Hida, Toyoaki
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (21)
  • [49] Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation
    Yoshimura, Yasushi
    Kurasawa, Mitsue
    Yorozu, Keigo
    Puig, Oscar
    Bordogna, Walter
    Harada, Naoki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) : 623 - 628
  • [50] Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    Ou, Sai-Hong Ignatius
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
12345